Drugs that lack single-agent activity: are they worth pursuing in combination?

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

(2016) Robert Z. Orlowski et al.   CANCER

Same Data; Different Interpretations

(2016) Bishal Gyawali et al.   JOURNAL OF CLINICAL ONCOLOGY

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

(2012) Jeffrey L. Wolf et al.   LEUKEMIA & LYMPHOMA

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions

(2010) Alberto Ocaña et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

(2009) K. L. Blackwell et al.   ANNALS OF ONCOLOGY